M&T Bank Corp Sells 402,012 Shares of Sanofi $SNY

M&T Bank Corp lowered its stake in Sanofi (NASDAQ:SNY) by 97.4% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 10,531 shares of the company’s stock after selling 402,012 shares during the quarter. M&T Bank Corp’s holdings in Sanofi were worth $510,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of SNY. CSM Advisors LLC purchased a new position in Sanofi during the 3rd quarter valued at about $18,244,000. Caprock Group LLC bought a new stake in shares of Sanofi in the third quarter worth approximately $1,347,000. Natixis Advisors LLC grew its stake in shares of Sanofi by 11.8% in the third quarter. Natixis Advisors LLC now owns 3,113,381 shares of the company’s stock worth $146,952,000 after acquiring an additional 327,569 shares during the period. Assetmark Inc. grew its stake in shares of Sanofi by 25.0% in the third quarter. Assetmark Inc. now owns 357,172 shares of the company’s stock worth $16,859,000 after acquiring an additional 71,356 shares during the period. Finally, XY Capital Ltd bought a new stake in Sanofi during the third quarter valued at approximately $1,603,000. Institutional investors own 14.03% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on SNY shares. Argus upgraded shares of Sanofi to a “strong-buy” rating in a research report on Monday, April 27th. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Sanofi in a research report on Friday, January 16th. Barclays lowered shares of Sanofi from an “overweight” rating to an “equal weight” rating in a research report on Tuesday, January 6th. UBS Group restated a “neutral” rating on shares of Sanofi in a research report on Friday, January 16th. Finally, Morgan Stanley set a $52.00 target price on shares of Sanofi in a research report on Friday. Two analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $51.00.

Sanofi Price Performance

SNY stock opened at $46.08 on Friday. Sanofi has a one year low of $43.32 and a one year high of $55.73. The company’s fifty day moving average price is $46.39 and its 200-day moving average price is $47.90. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.22 and a current ratio of 1.01. The company has a market capitalization of $112.39 billion, a PE ratio of 12.87, a price-to-earnings-growth ratio of 1.14 and a beta of 0.35.

Sanofi Increases Dividend

The business also recently announced an annual dividend, which will be paid on Wednesday, June 3rd. Stockholders of record on Monday, May 4th will be issued a $2.4225 dividend. This represents a dividend yield of 502.0%. This is a boost from Sanofi’s previous annual dividend of $2.04. The ex-dividend date of this dividend is Monday, May 4th. Sanofi’s payout ratio is presently 44.69%.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.